比美吉珠单抗双重中和白细胞介素17A和17F治疗银屑病患者:BE ABLE 1(一项12周随机双盲安慰剂对照2b期试验)结果
BE ABLE 1是一项12周随机双盲安慰剂对照2b期试验,评估比美吉珠单抗(选择性中和IL-17A和IL-17F的单克隆抗体)治疗中重度斑块状银屑病的疗效与安全性;第12周PASI90应答率在比美吉珠单抗组为46.2%-79.1%,安慰剂组为0%(P<.0001),呈显著剂量依赖性;不良事件发生率比美吉珠单抗组61%、安慰剂组36%;原文局限性为无活性对照。
要点
- 第12周PASI90应答率比美吉珠单抗组46.2%-79.1%,安慰剂组0%(P<.0001),呈显著剂量依赖性。
- 第12周PASI100应答率比美吉珠单抗组27.9%-60.0%,安慰剂组0%(P≤.0002)。
- 治疗中出现的不良事件比美吉珠单抗组126/208(61%),安慰剂组15/42(36%)。
核心结论
- 比美吉珠单抗双重中和IL-17A和IL-17F可为银屑病患者提供快速且显著的临床改善,未发现意外或剂量相关的安全性问题。
研究设计与样本
- 双盲、安慰剂对照2b期研究(NCT02905006)。
- 患者按1:1:1:1:1:1随机分组,每4周皮下注射比美吉珠单抗64 mg、160 mg、160 mg(320 mg负荷剂量)、320 mg、480 mg或安慰剂。
- 主要终点为第12周银屑病面积严重程度指数改善≥90%(PASI90)。
主要发现
- 第12周PASI90呈显著剂量依赖性应答(P<.0001)。
- 第12周PASI90应答率比美吉珠单抗组为46.2%-79.1%,安慰剂组为0%(所有剂量P<.0001)。
- 所有剂量组与安慰剂相比,所有次要终点较基线均有显著改善(第8周PASI90、第12周PASI75、第12周PASI100、第8周和第12周研究者总体评估清除或几乎清除;P≤.0003)。
- 第12周PASI100应答率比美吉珠单抗组为27.9%-60.0%,安慰剂组为0%(所有剂量P≤.0002)。
- 治疗中出现的不良事件:比美吉珠单抗组126/208(61%),安慰剂组15/42(36%)。
关键数值与推荐
- 第12周PASI90应答率:比美吉珠单抗组46.2%-79.1% vs 安慰剂组0%(所有剂量P<.0001)。
- 第12周PASI100应答率:比美吉珠单抗组27.9%-60.0% vs 安慰剂组0%(所有剂量P≤.0002)。
- 所有次要终点与安慰剂相比显著改善(P≤.0003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无活性对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neutralizing interleukin (IL) 17F in addition to IL-17A might provide a more complete and specific approach to inhibiting inflammation. OBJECTIVE: Assess the efficacy and safety of bimekizumab, a monoclonal antibody that potently and selectively neutralizes IL-17A and IL-17F, in patients with moderate-to-severe plaque psoriasis. METHODS: Double-blinded, placebo-controlled phase 2b study (NCT02905006). Patients (randomized 1:1:1:1:1:1) received subcutaneous bimekizumab every 4 weeks at doses of 64 mg, 160 mg, 160 mg with 320 mg loading dose, 320 mg, 480 mg, or placebo. Primary endpoint was ≥90% reduction in Psoriasis Area Severity Index (PASI90) at week 12. RESULTS: There was a significant (P < .0001) dose-dependent response for PASI90 (week 12); more patients achieved PASI90 in the bimekizumab groups (46.2%-79.1%) than patients in the placebo group (0%; P < .0001 all doses). Across all doses, there were significant improvements from baseline for all secondary endpoints (PASI90 week 8, PASI75 week 12, PASI100 week 12, and Investigators Global Assessment clear or almost clear weeks 8 and 12; P ≤ .0003) compared with placebo. More bimekizumab-treated patients than placebo-treated patients achieved PASI100 (week 12) (27.9%-60.0% vs 0%; P ≤ .0002 all doses). Treatment-emergent adverse events were reported by 126 of 208 (61%) bimekizumab-treated patients and 15 of 42 (36%) placebo-treated patients. LIMITATIONS: No active comparator. CONCLUSION: Dual neutralization of IL-17A and IL-17F with bimekizumab provided rapid and substantial clinical improvements in patients with psoriasis, with no unexpected or dose-related safety findings.
引用
- Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018. PMID: 29609013. doi:10.1016/j.jaad.2018.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。